EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Resistance to EGFR Inhibitors in NSCLC: Mechanistic Insights and Emerging Therapies

Rita Khoury iD, Chris Raffoul iD, Colette Hanna, Khalil Saleh iD, Annoir Shayya iD, Meriana Nahouli, Hady Ghanem iD

International Journal of Molecular Sciences · 09.06.2026 · 27 (12) · 5197

DOI: 10.3390/ijms27125197 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 09.06.2026. Verfasst von Rita Khoury und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology & Oncology, Lebanese American University Medical Center-Rizk Hospital, Beirut P.O. Box 11-3288, Lebanon. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 158 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-small cell lung cancer (NSCLC) accounts for up to 85% of lung cancer cases, with activating EGFR mutations present in 10–15% of Western and up to 35% of Asian patients. EGFR tyrosine kinase inhibitors (TKIs) have transformed management, with first-line osimertinib demonstrating a median progression-free survival (PFS) of 18.9 months and overall survival (OS) of 38.6 months in the FLAURA trial. However, resistance inevitably develops, most commonly via T790M mutations (~50% of cases after first- and second-generation TKIs), and after osimertinib, through diverse mechanisms including C797S mutations, MET/HER2 amplification, and histologic transformation. Emerging strategies to overcome resistance include next-generation TKIs, combination targeted therapies, downstream pathway inhibitors, immunotherapy approaches, and antibody–drug conjugates. Understanding these mechanisms is critical for optimizing patient outcomes and guiding personalized therapeutic approaches. This review discusses current strategies to delay or overcome resistance and highlights emerging therapeutic avenues with the potential to reshape the management of EGFR-mutant NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, NeoplasmProtein Kinase InhibitorsCarcinoma, Non-Small-Cell LungLung NeoplasmsAntineoplastic AgentsHumansErbB ReceptorsMutationAnimalsMolecular Targeted Therapy

Stichwörter der Autor:innen

EGFR inhibitors resistanceEGFR mutationNSCLC

Substanzen

ErbB ReceptorsProtein Kinase InhibitorsEGFR protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Division of Hematology & Oncology, Lebanese American University Medical Center-Rizk Hospital, Beirut P.O. Box 11-3288, Lebanon.
  • Department of Internal Medicine at VCU Health, Richmond, VA 23298, USA.
  • International Department, Gustave Roussy Cancer Campus, 94800 Villejuif, France.

ORCID-Profile: Rita Khoury, Chris Raffoul, Khalil Saleh, Annoir Shayya, Hady Ghanem

Zitieren

APA

Khoury, R., Raffoul, C., Hanna, C., Saleh, K., Shayya, A., Nahouli, M., & Ghanem, H. (2026). Resistance to EGFR Inhibitors in NSCLC: Mechanistic Insights and Emerging Therapies. International Journal of Molecular Sciences, 27(12), 5197. https://doi.org/10.3390/ijms27125197

Vancouver

Khoury R, Raffoul C, Hanna C, Saleh K, Shayya A, Nahouli M, et al. Resistance to EGFR Inhibitors in NSCLC: Mechanistic Insights and Emerging Therapies. International Journal of Molecular Sciences. 2026;27(12):5197. doi:10.3390/ijms27125197

BibTeX
@article{Khoury2026,
  author = {Khoury, Rita and Raffoul, Chris and Hanna, Colette and Saleh, Khalil and Shayya, Annoir and Nahouli, Meriana and Ghanem, Hady},
  title = {Resistance to EGFR Inhibitors in NSCLC: Mechanistic Insights and Emerging Therapies},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {12},
  pages = {5197},
  doi = {10.3390/ijms27125197}
}
Kostenlos starten →